YOLFTbeta
Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc

VRCA · NASDAQ · Healthcare / Biotechnology

3.56USD-0.16 (-4.30%)

Price History

Full chart

Market Stats

Previous Close3.72
Open3.75
Day Range3.40 – 3.92
52-Week Range3.28 – 9.82
Volume18.66K
Market Cap79.02M
P/E (TTM)0.00
Forward P/E0.00
EPS-1.83
Dividend Yield0.00%
Beta1.50
50-Day Avg5.04
200-Day Avg6.12

About

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jayson M. Rieger M.B.A., Ph.D.
  • Employees76
  • Headquarters44 West Gay Street, West Chester, PA, United States, 19380, USA
  • Websitehttps://www.verrica.com

Leadership

  • Dr. Jayson M. Rieger M.B.A., Ph.D.President, CEO & Director · b. 1976
  • Mr. John J. Kirby CPAInterim Chief Financial Officer · b. 1972
  • Dr. Noah L. Rosenberg M.D.Chief Medical Officer · b. 1967
  • Mr. David ZawitzCOO, Chief Legal Officer & Secretary · b. 1981
  • Mr. Eugene ScavolaExecutive Vice President of Technical Operations
  • Dr. Bradley J. Catalone MBA, Ph.D.Head of Drug Development
  • Mr. Chris ChapmanChief Commercial Officer

Financials

Income Statement

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000012.00M12.00M9.03M5.12M7.57M35.58M
Growth (%)-----0.00%-24.73%-43.27%+47.66%+370.22%
Cost of Revenue0020.29K257.20K229.00K472.00K725.00K746.00K2.74M3.44M
Gross Profit00-20.29K-257.20K-229.00K11.53M8.31M4.38M4.83M32.14M
Gross Margin-----1.91%96.07%91.97%85.44%63.79%90.33%
Operating Expense1.91M4.46M21.86M29.82M39.95M42.44M29.60M70.14M70.75M44.08M
Operating Income-1.91M-4.46M-21.88M-30.08M-40.18M-30.91M-21.30M-65.76M-65.92M-11.94M
Operating Margin-----334.84%-257.57%-235.78%-1283.35%-871.25%-33.56%
EBITDA-1.91M-4.46M-20.63M-29.82M-39.43M-30.31M-21.60M-62.20M-65.90M-9.36M
EBITDA Margin-----328.60%-252.61%-239.12%-1213.84%-870.98%-26.32%
Net Income-1.91M-4.46M-20.65M-27.95M-45.50M-35.08M-24.49M-67.00M-76.58M-17.89M
Net Income Margin-----379.14%-292.33%-271.11%-1307.47%-1012.15%-50.27%
R&D1.71M3.73M12.83M15.44M15.67M15.93M12.20M20.30M11.84M8.86M
R&D as % of Total Revenue----130.61%132.74%135.05%396.08%156.49%24.89%
Interest Expense02.00K003.03M4.29M2.17M3.96M9.41M7.74M
Interest Expense % of Total Revenue----25.27%35.79%24.05%77.32%124.40%21.76%

Balance Sheet

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets544.00K9.08M91.91M68.42M74.15M80.13M44.72M81.60M54.13M47.13M
Total Liabilities3.21M16.12M2.48M3.41M41.17M47.52M4.69M61.83M63.99M22.39M
Total Equity-2.66M-7.04M89.43M65.02M32.99M32.60M40.03M19.76M-9.86M24.74M
Cash527.00K8.66M10.27M9.24M10.69M15.75M34.27M69.55M46.33M30.15M
Total Debt36.00K--188.00K37.21M43.41M1.53M45.51M45.94M1.63M
Net Debt-527.00K-8.66M-10.27M-9.05M26.52M27.66M-32.75M-24.04M-390.00K-28.52M

Cash Flow

Currency: USD2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.61M-4.58M-17.87M-27.41M-30.21M-27.58M-18.65M-38.58M-60.93M-17.63M
Investing Cash Flow-79.89M-79.89M-79.89M25.95M-3.58M-998.00K54.04M-362.00K-19.00K-
Financing Cash Flow483.00K12.72M99.38M423.00K35.23M33.65M-16.87M74.21M37.73M1.45M
Capital Expenditure774.00K774.00K774.00K682.00K1.47M883.00K302.00K362.00K27.00K0
Free Cash Flow-1.61M-4.58M-18.65M-28.09M-31.68M-28.46M-18.95M-38.94M-60.95M-17.63M
FCF to OCF100.00%100.00%104.33%102.49%104.87%103.20%101.62%100.94%100.04%100.00%

Earnings

Report DateMay 4, 2017Feb 3, 2018Jun 15, 2018Aug 7, 2018Nov 7, 2018Mar 7, 2019May 7, 2019Aug 7, 2019Nov 6, 2019Mar 13, 2020May 7, 2020Aug 5, 2020Nov 9, 2020Mar 4, 2021May 7, 2021Aug 10, 2021Nov 12, 2021Mar 2, 2022May 9, 2022Aug 11, 2022Nov 7, 2022Mar 6, 2023May 9, 2023Aug 8, 2023Nov 9, 2023Feb 29, 2024May 13, 2024Aug 14, 2024Nov 4, 2024Feb 26, 2025May 13, 2025Aug 12, 2025Nov 14, 2025Mar 11, 2026May 13, 2026Aug 6, 2026Nov 13, 2026
EPS Estimate0.000.000.00-3.60-2.50-0.27-2.85-3.40-2.70-2.95-0.38-4.60-4.33-0.42-3.43-4.07-5.10-0.50-4.47-3.20-1.00-0.19-1.70-2.00-3.90-0.53-4.40-4.02-3.87-0.24-1.36-0.83-0.06-0.64-0.59-0.47-0.63
EPS Actual-0.02-0.18-0.08-5.10-2.70-0.30-3.00-2.80-2.40-3.10-0.39-3.80-4.20-0.52-0.40-4.30-4.70-0.35-3.10-3.700.34-0.14-1.50-2.40-5.40-0.53-4.40-3.70-4.90-0.20-1.000.25-0.03-0.51-0.45-0.54-
Surprise----41.67%-8.00%-11.11%-5.26%17.65%11.11%-5.08%-2.63%17.39%3.00%-23.81%88.34%-5.65%7.84%30.00%30.65%-15.63%134.00%26.32%11.76%-20.00%-38.46%0.00%0.00%7.96%-26.61%16.82%26.47%130.12%50.00%20.31%22.98%-14.89%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-market-After-hoursAfter-hours

Key Statistics & Ratios

Market Cap79.02M
Enterprise Value70.84M
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.61
Price / Book18.63
EPS-1.83
Book Value0.251
Revenue (TTM)30.32M
Gross Profit (TTM)11.43M
EBITDA-25.96M
Profit Margin-102.84%
Operating Margin-194.46%
Return on Equity-240.36%
Return on Assets-43.98%
Shares Outstanding17.18M
Shares Float12.41M
Beta1.50
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 13.83
  • Strong Buy
    2
  • Hold
    3

Ownership Breakdown

Institutions
27.14%
Insiders
49.00%
Retail / Other
23.86%

Top Institutional Holders

  • Caligan Partners LP
    923.91K5.38%
  • Cannell Capital LLC
    783.92K4.56%
  • Affinity Asset Advisors, LLC
    707.34K4.12%
  • Armistice Capital, LLC
    518.18K3.02%
  • Velan Capital Investment Management LP
    471.56K2.75%
  • BOOTHBAY FUND MANAGEMENT, LLC
    280.73K1.63%
  • Vanguard Capital Management, LLC
    188.76K1.10%
  • Marshall Wace Asset Management Ltd
    140.50K0.82%
  • Geode Capital Management, LLC
    138.92K0.81%
  • Stonepine Capital Management Llc
    99.73K0.58%
  • Squarepoint Ops LLC
    75.21K0.44%
  • Vanguard Fiduciary Trust Co
    65.10K0.38%
  • Jane Street Group LLC
    49.21K0.29%
  • Two Sigma Investments LLC
    40.83K0.24%
  • BlackRock Inc
    38.55K0.22%
  • Renaissance Technologies Corp
    32.36K0.19%
  • Northern Trust Corp
    31.58K0.18%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    216.44K1.26%
  • Fidelity Extended Market Index
    60.99K0.35%
  • iShares Micro-Cap ETF
    36.01K0.21%

Stock Splits

  • Jul 25, 20251:10